Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system

被引:610
作者
Creemers, MCW
Franssen, MJAM
van't Hof, MA
Gribnau, FWJ
van de Putte, LBA
van Riel, PLCM
机构
[1] Univ Med Ctr St Radboud, Dept Rheumatol, NL-6500 HB Nijmegen, Netherlands
[2] St Maartenshosp, Dept Rheumatol, Nijmegen, Netherlands
[3] Catholic Univ, Dept Med Stat, Nijmegen, Netherlands
[4] Univ Med Ctr St Radboud, Dept Clin Pharmacol, NL-6500 HB Nijmegen, Netherlands
关键词
D O I
10.1136/ard.2004.020503
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To develop and validate an extensive radiographic scoring system for ankylosing spondylitis (AS). Methods: The Stoke Ankylosing Spondylitis Spinal Score (SASSS) was modified by adding a score for the cervical spine and defining squaring. This modified SASSS (mSASSS) is the sum of the lumbar and cervical spine score (range 0 72). 370 lateral views of the lumbar and cervical spine were used for development of the mSASSS, standardisation of observers, and for studying reliability. In a 48 week NSAID study of 57 patients, change over time and construct validity were studied. Results: Interobserver correlations of the lumbar and cervical spine scores were good (r > 0.95). The interobserver duplicate error was 0.55 in a range from 0 to 36. The mean change in the cervical and lumbar spine scores between weeks 0 and 48 of all patients was 1.45 (range 0-6.0) and 1.06 (0-5.0), respectively (paired t testing, p < 0.001). Change in radiological score was seen in 36/57 (63%) patients (lumbar and cervical spine 11, cervical spine 12, lumbar spine 13 patients). Conclusion: The mSASSS is useful for assessing extensive radiographic damage in AS. It is reliable, detects changes over 48 weeks, and shows a satisfactory face and construct validity.
引用
收藏
页码:127 / 129
页数:3
相关论文
共 17 条
[1]  
ADRICHEM JAM, 1973, SCAND J RHEUMATOL, V2, P87
[2]   Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis [J].
Brandt, J ;
Khariouzov, A ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Grassnickel, L ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (06) :1667-1675
[3]   Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis -: An open, observational, extension study of a three-month, randomized, placebo-controlled trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Golder, W ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Reddig, J ;
Sieper, J .
ARTHRITIS AND RHEUMATISM, 2003, 48 (08) :2224-2233
[4]   THE NATURAL DISEASE COURSE OF ANKYLOSING-SPONDYLITIS [J].
CARETTE, S ;
GRAHAM, D ;
LITTLE, H ;
RUBENSTEIN, J ;
ROSEN, P .
ARTHRITIS AND RHEUMATISM, 1983, 26 (02) :186-190
[5]  
Creemers MCW, 1996, BRIT J RHEUMATOL, V35, P867
[6]  
CREEMERS MCW, 1994, BRIT J RHEUMATOL, V33, P842
[7]   2ND-LINE TREATMENT IN SERONEGATIVE SPONDYLARTHROPATHIES [J].
CREEMERS, MCW ;
VANRIEL, PLCM ;
FRANSSEN, MJAM ;
VANDEPUTTE, LBA ;
GRIBNAU, FWJ .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 1994, 24 (02) :71-81
[8]  
CREEMERS MCW, 1994, THESIS CATHOLIC U NI
[9]  
DOMJAN L, 1990, J RHEUMATOL, V17, P663
[10]  
Mackay K, 1998, ARTHRITIS RHEUM-US, V41, P2263, DOI 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.3.CO